A dataset on formulation parameters and characteristics of drug-loaded PLGA microparticles
Frequently asked questions about GLP-1 patches Are GLP-1 patches available in the UK
Oral metabolic franchise, a broader portfolio of oral small molecule candidates targeting metabolic disease beyond the lead GLP-1 program Recent Highlights: In May 2026, Structure reported positive end-of-Phase 2 feedback from the FDA for aleniglipron, clearing the way to begin a Phase 3 registrational program for chronic weight management in Q3 2026
Notably, discontinuation is associated with weight regain and partial or complete reversal of improvements in cardiometabolic risk factors, including inflammatory markers, blood pressure, lipid profile, and blood glucose levels
How to manage diarrhea while on GLP-1 medications
Intestinal PermeationEnhancers for Oral Delivery of Macromolecules: A Comparison between Salcaprozate Sodium (SNAC) and Sodium Caprate (C10)